The Efficacy of Electroconvulsive Therapy Studies – Ugo Cerletti and Lucio Bini

In the annals of twentieth-century medicine, few therapeutic innovations have provoked such profound intellectual debate, ethical scrutiny, and transformative clinical utility as electroconvulsive therapy (ECT). Conceived during an era when institutional psychiatry was largely characterized by custodial confinement and therapeutic nihilism, the advent of convulsive interventions marked a decisive paradigm shift toward biological and somatic mechanisms of disease resolution. Prior to the late 1930s, severe neuropsychiatric conditions—most notably schizophrenia (then frequently conceptualized through Emil Kraepelin’s framework of dementia praecox) and refractory affective psychoses—lacked efficacious, reproducible treatments. Patients admitted to mental institutions frequently faced decades of progressive cognitive deterioration, catatonic immobility, or unremitting melancholic agitation, with little hope of discharge or social reintegration.

The pivotal breakthrough occurred in April 1938 at the Clinic for Nervous and Mental Diseases at the Sapienza University of Rome, where neuropsychiatrist Ugo Cerletti and his collaborator, the physician and biophysicist Lucio Bini, successfully induced a therapeutic generalized epileptic seizure in a human subject using a calibrated trans-cranial alternating electrical current. Far from being a serendipitous accident, this historic achievement was the culmination of an exhaustive, systematic research program integrating comparative neuropathology, bioengineering, animal physiology, and careful clinical titration. Cerletti’s clinical acumen and extensive neuropathological training under the founders of modern histology, combined with Bini’s technical mastery of electrophysiology and apparatus design, allowed the Roman school to surpass the crude, dangerous, and terror-inducing chemical convulsive methods of their contemporaries.

This treatise provides an exhaustive historical, clinical, and neurobiological examination of Cerletti and Bini’s seminal efficacy studies. By analyzing the biophysical principles, preclinical safety methodologies, clinical trial data, and subsequent global dissemination of their work, this paper delineates how an empirical somatic intervention transformed institutional psychiatry. Moreover, it explores the theoretical mechanistic models posited by the Roman investigators—from humoral “acroagonine” hypotheses to neurovegetative resetting—and traces how these early scientific inquiries laid the groundwork for modern neuroimaging, neuroplasticity concepts, and contemporary guidelines that continue to validate electroconvulsive therapy as one of the most acutely effective treatments for severe affective and psychotic illness.

1. Historical Context: Somato-Therapeutic Paradigms in 1930s Neuropsychiatry

The decade of the 1930s represents one of the most volatile and creatively daring epochs in the history of neuropsychiatry. As the limitations of purely custodial institutionalization and speculative psychodynamic models became glaringly apparent in the face of severe, deteriorating psychotic and affective states, academic clinics across Continental Europe turned their focus toward physical, somatic interventions capable of altering the biological substrate of the central nervous system.

1.1 The Rise of Biological Psychiatry and Empirical Therapeutics

The early twentieth century witnessed a deep epistemological rift within psychiatry. While psychoanalytic and psychodynamic paradigms gained substantial cultural and clinical traction in outpatient psychotherapy and the management of milder neurotic spectrum disorders, they proved conspicuously ineffective when applied to severe psychoses within large institutional settings. Asylums across Europe and North America were overcrowded with hundreds of thousands of chronic patients diagnosed with dementia praecox, catatonia, and intractable melancholia. The prevailing institutional atmosphere was one of therapeutic nihilism; psychiatric alienists acted primarily as diagnosticians, classifiers, and custodians rather than curative practitioners.

In response to this institutional crisis, a vanguard of European researchers began to reassert the tenets of biological psychiatry, arguing that severe psychiatric illnesses were rooted in structural neuropathology, neurochemical dysregulation, or fundamental neurophysiological derangements. Influenced by the pioneering histopathological work of investigators such as Alois Alzheimer and Franz Nissl, neuropsychiatric institutes began establishing specialized somatic research laboratories. These academic environments—most prominently in Vienna, Budapest, Munich, and Rome—sought to discover empirical therapeutic modalities that could directly modify cerebral function.

Empirical therapeutics during this era operated on the premise that profound physiological perturbations could fundamentally alter, interrupt, or reset disordered mental processes. Rather than waiting for a complete etiology of schizophrenia or affective psychosis to be elucidated at the molecular level, clinicians systematically tested dramatic biological stressors, including prolonged pyrexia, prolonged pharmacologically induced sleep, and severe metabolic shifts. This empirical turn laid the institutional, philosophical, and methodological foundation for the dramatic introduction of convulsive therapies throughout the mid-1930s.

1.2 Precursor Shock Therapies: Sakel and von Meduna

The immediate precursors to electroconvulsive therapy were two distinct somatic interventions that gained rapid international prominence: insulin coma therapy and chemical convulsion therapy. In 1933, the Viennese physician Manfred Sakel introduced insulin coma therapy (ICT), positing that massive doses of insulin capable of inducing profound hypoglycemic coma could ameliorate the symptoms of schizophrenia. Sakel hypothesized that hypoglycemia temporarily dampened or neutralized the phylogenetically younger, hyperactive cortical layers, thereby allowing deeper, vegetative restorative processes to re-establish psychic equilibrium. While ICT demonstrated unprecedented clinical improvements in selected cohorts, it was extraordinarily labor-intensive, required dedicated specialized units, and carried a staggering mortality rate (frequently estimated between 1% and 5%) alongside the chronic threat of irreversible hypoglycemic encephalopathy and uncal herniation.

Concurrently, the Hungarian neuropathologist Ladislas von Meduna pursued an entirely different biological rationale. Meduna observed what he believed to be a fundamental biological antagonism between epilepsy and schizophrenia. Drawing on post-mortem histopathological studies, Meduna noted that individuals with chronic epilepsy demonstrated a proliferation of cerebral glial cells, whereas brains from schizophrenic patients exhibited a distinct deficiency of glia. Furthermore, clinical lore suggested that schizophrenic patients who spontaneously developed epileptic seizures frequently experienced transient or prolonged remissions of their psychotic symptoms. Operating on this theoretical antagonism, Meduna sought an exogenous, chemical method to safely induce generalized epileptic seizures.

After initially experimenting with intramuscular injections of camphor dissolved in oil—which proved highly erratic due to prolonged, unpredictable absorption rates—Meduna turned to the synthetic water-soluble analeptic pentylenetetrazol (marketed under the trade name Metrazol or Cardiazol). Intravenous administration of Metrazol reliably precipitated generalized tonic-clonic convulsions within seconds or minutes. However, Metrazol convulsive therapy possessed devastating clinical drawbacks. The interval between the intravenous push and the loss of consciousness was characterized by an overwhelming sensation of impending doom, intense suffocation, autonomic storm, and visceral panic. This subjective horror was so severe that patients routinely developed acute anticipatory anxiety, requiring physical restraint by multiple orderlies to receive subsequent injections. Additionally, the violent, uncontrolled muscular contractions produced a catastrophic incidence of musculoskeletal trauma, including limb dislocations and vertebral compression fractures.

1.3 The Search for a Controlled Epileptogenic Method

The operational liabilities of both insulin coma and chemical convulsive therapies catalyzed an intensive international effort to identify an alternative epileptogenic stimulus that could circumvent the biological and psychological hazards of Metrazol. The ideal convulsive method required precise titratability, instantaneous induction of unconsciousness to abolish the terrifying pre-ictal panic state, immediate cessation of the stimulus without lingering biochemical toxicity, and exceptional reproducibility across repetitive administrations.

Electric current quickly emerged as the most compelling theoretical candidate. Unlike systemic chemical convulsants, which depended upon variable pharmacokinetics, hepatic metabolism, and erratic blood-brain barrier permeability, electrical currents could be quantified precisely in terms of voltage, amperage, pulse duration, and frequency. Biophysically, alternating current applied directly across the cranium possessed the capacity to depolarize vast ensembles of cortical neurons simultaneously, initiating an epileptogenic discharge with millisecond accuracy while avoiding the lingering pharmacological toxicity seen with analeptic drugs.

At the Clinic for Nervous and Mental Diseases at the University of Rome, Ugo Cerletti closely monitored the international reports detailing Meduna’s Metrazol trials. Cerletti was convinced of the therapeutic validity of the generalized seizure itself, yet he recognized that Metrazol was too crude, terrifying, and dangerous to serve as a sustainable, humane medical therapy. The intellectual climate at the University of Rome was distinctly characterized by rigorous experimental neurophysiology and advanced neuropathology. Cerletti realized that if electric current could be harnessed to safely trigger a generalized cerebral paroxysm without inducing thermal damage, cardiac arrest, or fatal respiratory failure, modern neuropsychiatry would possess an unprecedented therapeutic instrument.

2. The Genesis of Electroconvulsive Investigation: Cerletti and Bini’s Collaborative Foundation

The realization of electroconvulsive therapy was not an isolated stroke of clinical inspiration, but rather the structural consequence of an extraordinarily synergistic collaboration between two investigators whose distinct skill sets complemented each other with scientific precision: Ugo Cerletti, the master neuropathologist and academic clinician, and Lucio Bini, the brilliant young physician-biophysicist.

2.1 Ugo Cerletti: Neuropathological Rigor and Epileptology

Born in 1877 in Conegliano, Italy, Ugo Cerletti was a titan of European neuropsychiatry long before he ever applied an electrical electrode to a psychiatric patient. His scientific pedigree was impeccable: he had completed rigorous postdoctoral training in histology and neuropathology under the direct mentorship of Franz Nissl in Heidelberg, Alois Alzheimer in Munich, and Gaetano Perusini in Rome. Cerletti had spent decades examining the cellular micro-architecture of the brain, publishing seminal papers on microglial activation, the pathological anatomy of neurosyphilis, cerebral changes in epidemic encephalitis, and the histopathology of endemic cretinism.

Crucially, Cerletti possessed a deep and enduring research interest in the fundamental pathophysiology of epilepsy. As early as 1932, while serving as the director of the Neuropsychiatric Clinic in Genoa, Cerletti had initiated animal experiments utilizing electrical shocks to induce experimental seizures in dogs. His primary scientific objective at that time was not psychiatric therapy, but rather the neuropathological examination of the brain after repeated epileptic attacks. Cerletti was fascinated by the question of whether epileptic seizures produced structural parenchymal damage—such as hippocampal Ammon’s horn sclerosis—or whether such cellular lesions were merely the secondary artifacts of post-ictal hypoxia and cerebral edema.

When Cerletti assumed the prestigious chair of the Department of Neuropsychiatry at the Royal University of Rome in 1935, he brought this profound investigative foundation with him. He established a state-of-the-art histological and neurophysiological research laboratory, assembling a cadre of brilliant young researchers. Possessing an encyclopedic understanding of cerebral blood flow, vascular permeability, and neuronal ultrastructure, Cerletti approached the concept of therapeutic convulsion not as a reckless empirical gamble, but as a formal biological challenge that demanded absolute pathological rigor and comprehensive safety verification.

2.2 Lucio Bini: Biophysical Expertise and Instrument Design

While Cerletti provided the overarching theoretical vision and neuropathological leadership, the technical realization of electrical seizure induction required a level of biophysical and electrical engineering acumen that few clinicians possessed. This critical role was filled by Lucio Bini, an exceptionally talented young assistant at the Roman clinic. Bini possessed a profound comprehension of electrophysiology, bio-impedance, and circuit design, which set him apart from conventional contemporary psychiatrists.

Cerletti tasked Bini with a monumental objective: to review the entire global literature on electrical trauma, electrocution dynamics, and commercial currents, and subsequently to engineer a prototype medical apparatus capable of delivering an electric current of precisely determined physical parameters directly to the human cranium. Bini recognized from the outset that the primary danger of commercial electrical current lay in its path through the human body. Industrial electrocution deaths almost universally resulted from current pathways traversing the thoracic cavity, precipitating immediate cardiac ventricular fibrillation, rather than from irreversible destruction of brain tissue.

Working diligently in the clinic’s laboratories, Bini set out to formulate the biophysical parameters necessary to achieve the desired cerebral discharge without endangering the cardiovascular system. He calculated the safe voltage ranges, electrical impedances of the scalp and skull bones, and the exact millisecond time windows necessary to exceed the neuronal chronaxie and rheobase thresholds without generating significant thermal heating or structural parenchymal burns. Bini’s conceptual leap—that electricity could be administered as a precisely dosed medical pharmacological agent—fundamentally transformed electrical stimulation from an uncontrolled electrocution hazard into a sophisticated, titratable neuropsychiatric intervention.

2.3 Interdisciplinary Synergy and Experimental Hypotheses

The collaboration between Cerletti and Bini was grounded in a lucid, tripartite scientific hypothesis. First, they hypothesized that the therapeutic efficacy observed in Meduna’s chemical convulsion trials was entirely dependent upon the neurophysiological event of the generalized bilateral tonic-clonic motor seizure itself, rather than upon any unique, endogenous chemical property of the pentylenetetrazol molecule. If this were true, an electrically provoked seizure would yield identical—or superior—clinical psychotropic outcomes.

Second, they theorized that a bilateral, generalized epileptiform paroxysm required a critical mass of synchronized cortical neuronal depolarization, which could be initiated reliably and instantaneously by passing an alternating current through the frontotemporal regions of the brain. They recognized that sub-convulsive electrical stimulations—which produced momentary muscular twitches or brief absences without a sustained, fully propagated grand mal seizure—would likely prove therapeutically inert and medically undesirable.

Third, Cerletti and Bini established an absolute methodological rule: no human patient would be subjected to electrical convulsive intervention until the physical safety thresholds, electrode placements, and neuropathological consequences had been systematically established through exhaustive, quantitative animal experimentation. They designed a deliberate sequence of investigations progressing methodically from small laboratory animals to large mammalian models, ensuring that cardiac arrhythmias, brain burns, and cellular necrosis could be ruled out beyond empirical doubt. This interdisciplinary synergy between clinical neuropathology and biophysical engineering established the highest standard of preclinical medical safety of its era.

3. Preclinical Laboratory Experiments: Animal Models and Biophysical Safety

Before introducing electroconvulsive methodology into the clinical psychiatric ward, Cerletti and Bini conducted an extensive series of laboratory investigations between 1935 and 1938. These experiments were designed to delineate the precise boundaries between lethal electrocution and safe, reversible seizure induction, establishing an evidentiary base that was historically unique among the somatic therapies of the early twentieth century.

3.1 Canine Studies and Determining Lethal Thresholds

The initial phase of Cerletti and Bini’s animal investigations focused on canine models within the experimental laboratories of the University of Rome. The researchers began by replicating and deconstructing existing literature on accidental electrocution. In early experiments, alternating currents were passed across various bodily vectors in dogs to systematically observe the physiological consequences on cardiac rhythm and respiration. These trials immediately revealed that when an electrical circuit was established between an electrode placed on the animal’s head and another placed on a limb or the chest—a common configuration in industrial accidents—the current pathway traversed the myocardium.

Under these trans-thoracic conditions, even modest electrical voltages and short current durations caused instantaneous ventricular fibrillation, sudden drop in arterial blood pressure, and irreversible cardiac arrest. The heart, desynchronized by the electrical vector cutting across the cardiac conduction system, disintegrated into fatal, chaotic fibrillatory twitches, rendering cerebral resuscitation impossible.

Cerletti and Bini then altered the electrode configuration, applying both electrical poles exclusively to the canine cranium in a bitemporal or fronto-occipital orientation. The experimental results were immediate and striking: when the current path was restricted strictly to the neurocranium, the animals did not suffer cardiac arrest or ventricular fibrillation. Instead, the electrical discharge precipitated an instantaneous, generalized epileptic seizure displaying the classic phases of tonic contraction followed by rhythmic clonic jerks, complete autonomic discharge, and a transient post-ictal comatose recovery state. The animals routinely recovered spontaneous respiration within seconds following the cessation of the motor seizure, regaining normal motor function and alertness without cardiovascular compromise. This crucial discovery proved that the primary mechanism of electrocution death was cardiac rather than cerebral, and that cranial localization completely insulated the heart from fatal current loops.

3.2 The Rome Slaughterhouse Experiments: Porcine Investigation

Despite their canine successes, Cerletti remained acutely cognizant of the anatomical and scale differences between canines and humans. The human cranium possesses a vastly thicker calvarium, a larger intracranial volume, and a much higher trans-cranial electrical impedance. Cerletti sought a mammalian model whose cranial thickness and cerebral mass closely approximated those of adult humans. This pursuit led him to a remarkable, unorthodox scientific setting: the municipal slaughterhouses of Rome (Mattatoio di Roma).

Cerletti had learned that the municipal abattoir was experimenting with an electrical stunning technique to immobilize pigs prior to slaughter. Intrigued by the safety implications, Cerletti and Bini obtained permission to conduct detailed physiological field measurements on site. At the slaughterhouse, the commercial operators applied large electrical pincers or tongs, clamped across the heads of the pigs, to pass commercial alternating currents through the animals’ skulls.

Cerletti observed that the electrical shock instantly rendered the pigs totally unconscious, precipitating a powerful epileptic seizure. Importantly, the animals did not drop dead from the electrical shock itself; rather, they remained in a state of flaccid, insensible post-ictal coma, during which the butcher would sever the carotid vessels to produce exsanguination. Cerletti realized that if the animals were not bled, they invariably survived the shock. To verify this, Cerletti purchased several pigs that were subjected to the standard electrical shock but spared from slaughter. Without exception, these animals spontaneously resumed normal respiration, transitioned out of the post-ictal stupor, regained their footing, and exhibited normal feeding and behavioral patterns without identifiable neurological deficits.

Cerletti and Bini brought specialized electrical metering apparatus to the slaughterhouse to measure the precise voltages, amperages, and temporal durations utilized in these stunning tongs. They recorded that pigs routinely withstood cranial electrical discharges of over 100 volts lasting several seconds—substantially exceeding the durations contemplated for clinical human use—without lethal consequence. This empirical verification provided definitive proof that the mammalian brain could endure substantial electrical currents without structural collapse or cardiac mortality.

3.3 Histopathological Verification of Cerebral Integrity

The final and most scientifically rigorous component of the preclinical phase addressed Cerletti’s core discipline: neuropathology. Skeptics within the medical community had voiced grave concerns that passing high-amperage alternating currents directly through the brain would inevitably cause microscopic thermal coagulations, petechial hemorrhages, cerebral edema, disruption of the blood-brain barrier, and irreversible neuronal cytolysis.

To settle this question definitively, Cerletti and his laboratory assistants subjected cohorts of experimental animals to repeated, daily electrically induced seizures, often delivering shock regimens far exceeding any anticipated human clinical course. Following these repeated seizure series, the animals were sacrificed at varying temporal intervals (immediately post-ictal, twenty-four hours later, and several weeks following treatment cessation). The brains were perfused with formalin, embedded in paraffin and celloidin, and processed using the most sophisticated histological staining techniques of the era, including Nissl cresyl violet staining for neuronal cytoarchitecture, Golgi silver impregnation for dendritic arborization, and Bielschowsky techniques for neurofibrils and axonal integrity.

Cerletti’s histological analysis demonstrated that regulated, brief trans-cranial alternating currents did not induce parenchymal burns, focal coagulations, or gross structural tissue destruction. The microscopic architecture of the cerebral cortex, the hippocampus, the basal ganglia, and the brainstem remained remarkably intact. While transient, reversible cellular swelling (cloudy swelling) and mild hyperemia of the leptomeningeal vessels were occasionally noted immediately following prolonged status-like events, these changes rapidly resolved. There was no evidence of significant gliosis or irreversible neuronal loss directly attributable to the electrical current itself. Cerletti concluded with scientific certainty that electrical seizure induction was a biophysically benign, structurally safe intervention that could be responsibly transitioned to human clinical investigation.

4. Technical Innovation: Engineering the Prototype Apparatus and Parameter Titration

Having established the biological safety of trans-cranial electrical currents in large mammals, Cerletti and Bini focused their attention on the technical architecture of the clinical apparatus. The transition from raw laboratory electrocution apparatuses to a refined, safe clinical instrument required pioneering advances in electrical circuitry, precise parameter titration, and impedance management.

4.1 Bini’s Original Electroshock Device Architecture

The first clinical electroshock machine, conceived and assembled by Lucio Bini in early 1938, was an exquisite example of functional, robust biomedical engineering. Rather than relying upon batteries or complex direct-current generators, Bini engineered the device to interface directly with the standard commercial municipal alternating current (AC) electrical grid of Rome, which operated at 125 volts and a frequency of 50 Hertz (Hz).

The architecture of the prototype was constructed around several primary components:

• A Step-Down/Step-Up Variable Isolation Transformer: This transformer served a dual function. Primarily, it provided galvanic isolation between the patient and the municipal power mains, protecting against ground faults and lethal line surges. Secondarily, it allowed the output voltage to be stepped up or down precisely.
• A Precision Rheostat and Potentiometer: Bini integrated a continuously variable wire-wound rheostat into the secondary circuit, enabling the operator to select and titrate the delivery voltage smoothly across a defined therapeutic spectrum, typically ranging from 50 to 150 volts.
• A Precision Spring-Driven Chronometer Switch: Given that the brain’s chronaxie threshold requires only fractions of a second to initiate self-propagating depolarization, the temporal duration of the electrical pulse had to be strictly controlled. Bini incorporated a specialized mechanical chronometric timing switch capable of opening and closing the secondary circuit with millisecond reliability, allowing exposure times calibrated between 0.1 and 0.5 seconds.
• Integrated Voltmeter and Milliammeter: Precision analog meters were placed in the circuit loop, allowing the research team to monitor the exact parameters delivered during each clinical trial run.

4.2 Electrode Design, Placement, and Impedance Management

The delivery of electrical energy from the apparatus into the human brain presented significant biophysical challenges, predominantly centered on the high ohmic resistance of human skin, subcutaneous adipose tissue, and the dense, poorly conductive calvarium. If electrode-to-skin resistance remained high, the application of electric current would generate localized heat via Joule’s law ($Q = I^2Rt$), resulting in painful thermal burns of the scalp and insufficient current penetration to the cerebral cortex.

To overcome this impediment, Bini engineered specialized electrode calipers. The apparatus consisted of an adjustable, spring-loaded metallic headset terminating in two circular lead contact plates, approximately 3 to 4 centimeters in diameter. These plates were designed to maintain firm, constant mechanical pressure against the patient’s temporal regions without shifting during the violent motor onset of the convulsion.

To minimize cutaneous impedance, Bini devised a rigorous skin-preparation protocol. The patient’s temporal skin was thoroughly degreased with ether or alcohol to eliminate insulating sebum. The metallic lead electrodes were wrapped in multiple layers of lint or flannel cloth, which were saturated with a warm, hypertonic saline solution (typically a 10% to 20% sodium chloride aqueous solution). This saline interface dramatically reduced the cutaneous contact resistance from several thousand ohms down to approximately 200 to 500 ohms. Furthermore, Bini incorporated an auxiliary low-voltage alternating circuit into the apparatus, which allowed the clinical team to measure the patient’s trans-cranial impedance directly before delivering the therapeutic shock, ensuring that the electrical pathway was optimal prior to firing.

4.3 Dosimetric Titration and Seizure Threshold Dynamics

Through systematic empirical testing, Cerletti and Bini elucidated the fundamental neurophysiological concept of the seizure threshold—the minimum quantity of electrical energy, defined by the relationship between voltage, current intensity, and temporal duration, necessary to trigger a self-propagating, generalized cerebral paroxysm. They observed that electrical stimulation operated under an absolute biological threshold law:

If the electrical parameters fell below this threshold, the patient experienced a sub-convulsive event (which Cerletti termed an assenza or “petit mal” equivalent). During a sub-convulsive shock, the patient displayed an immediate muscular spasm corresponding precisely to the duration of the current flow, followed by a brief second of respiratory arrest, transient facial pallor, and a momentary clouding of consciousness lasting several seconds, after which the patient returned to baseline without undergoing a motor convulsion. Cerletti and Bini recognized early on that these sub-convulsive stimulations possessed no psychiatric efficacy; they merely generated distress, disorientation, and subjective discomfort.

Conversely, once the electrical parameters crossed the individual’s seizure threshold, an all-or-none phenomenon took place. The applied current depolarized a critical volume of neurons in the frontal and temporal lobes, triggering an autonomous, self-sustaining avalanche of paroxysmal epileptic activity that propagated across the corpus callosum and down into the diencephalon and brainstem. At this point, the external electrical stimulus was irrelevant; the brain itself generated the generalized grand mal convulsion. Cerletti and Bini documented that seizure thresholds were highly individualized and could be influenced by a wide array of physiological variables, including the patient’s age, cranial circumference, skull bone density, basal metabolic state, and concurrent electrolyte balance.

5. The First Clinical Trials of April 1938: Methodological Protocol and Observations

In mid-April 1938, armed with extensive animal validation data and a meticulously calibrated prototype machine, Cerletti and Bini prepared to initiate the first human clinical trial. The event would become one of the most famous and extensively documented milestones in the history of neuropsychiatry.

5.1 Patient Selection Criteria: The Case of S.E.

The historical first human application of electroconvulsive therapy took place on a patient identified in the clinical records as S.E., a 39-year-old clerk from Milan. S.E. had been apprehended by the municipal police at the central railway terminal in Rome after wandering aimlessly through the station without an identity card, exhibiting severely disorganized, bizarre behavior, and attempting to board trains without a ticket. He was subsequently admitted to the Clinic for Nervous and Mental Diseases at the University of Rome under Cerletti’s clinical supervision.

Cerletti’s selection of S.E. as the pioneer candidate was governed by strict clinical and ethical considerations characteristic of the era. The patient presented with an advanced, deteriorating, and refractory form of schizophrenia. His clinical picture was dominated by complete mutism, profound catatonic posturing, bizarre and florid persecutory and religious delusions, auditory hallucinations, and total social alienation. When he did attempt to communicate, his speech was an unintelligible, fragmented “word salad” composed of neologisms and perseverative phrases. Exhaustive somatic evaluations, lumbar punctures, and serological analyses had definitively ruled out neurosyphilis, encephalitis, or space-occupying intracranial lesions.

Crucially, S.E. had been institutionalized for months without showing the slightest degree of spontaneous clinical improvement or responsiveness to standard institutional care. His prognosis was considered universally hopeless; under the clinical paradigms of 1938, he faced a lifetime of custodial confinement and progressive schizophrenic decay. Cerletti reasoned that because spontaneous recovery was impossible and existing chemical therapies had failed or were deemed excessively hazardous, S.E. represented the archetype of the patient who stood to benefit most profoundly from a novel, potentially transformative somatic intervention.

5.2 Sequential Trial Delivery and Empirical Adjustments

The historic first trial took place on April 11, 1938, within the clinical amphitheater of the Roman clinic, attended by Cerletti, Bini, and key assistants including Mario Accornero, Ferdinando Accornero, and Lothar Kalinowsky. The patient, S.E., was placed supine on a firm examination table. The bitemporal electrodes were applied following the rigorous hypertonic saline degreasing protocol. The atmosphere was charged with immense tension; the scientific community at large remained deeply skeptical, with many colleagues warning that passing commercial municipal currents through a human brain would cause instant cardiac arrest or immediate death.

Operating with extreme caution, Bini set the apparatus to an intentionally low, conservative parameter: 70 volts for a duration of 0.2 seconds. Cerletti depressed the firing switch. The machine delivered the current. Instantly, the patient’s skeletal muscles contracted in a brief, generalized spasm; his respiration halted for a brief second, and his face blanched. The current ceased. S.E. immediately opened his eyes, sat up on the couch, looked around the room with a bewildered expression, and then began to spontaneously sing a popular Italian song. No generalized epileptic seizure had occurred. The stimulus had fallen precisely into the sub-convulsive, “petit mal” threshold zone.

Recognizing that the electrical energy had been insufficient to ignite the necessary paroxysm, the team decided to reconvene. Over the subsequent days, after verifying that S.E. had suffered no neurological or cardiac deficits, the team planned a definitive, escalating trial. On April 20, 1938, S.E. was positioned once more. Bini escalated the voltage to 110 volts for 0.2 seconds. The stimulus triggered an immediate, powerful generalized motor response, but it aborted after several seconds, failing to develop into a fully propagated grand mal attack. While the clinical assistants debated whether to abandon the procedure for fear of ventricular irritability, Cerletti, confident in his porcine safety data, commanded an immediate re-titration.

Setting the dials to 110 volts for an extended duration of 0.5 seconds, Cerletti engaged the circuit. The effect was immediate, total, and dramatic. The electrical charge passed through the patient’s cranium, triggering an instantaneous loss of consciousness. The patient exhibited a brief, classic tonic phase lasting approximately ten to fifteen seconds, characterized by generalized skeletal extensor rigidity, clenched jaws, and cyanosis from respiratory arrest. This was seamlessly succeeded by a profound clonic phase lasting roughly thirty to forty seconds, featuring rhythmic, bilateral, synchronized muscular contractions throughout the trunk and extremities, accompanied by autonomic salivation and perspiration. Finally, the clonic jerks subsided, giving way to profound muscular flaccidity, stertorous breathing, and a deep, tranquil post-ictal sleep.

5.3 Immediate Post-Ictal Clinical and Cognitive Responses

As S.E. gradually emerged from the post-ictal coma into the light of the examination theater, the clinical team bore witness to a phenomenon that astounded the psychiatric world. The patient, who had spent months in impenetrable mutism and bizarre delusional fragmentation, opened his eyes, looked directly into Cerletti’s face, and calmly, coherently inquired in a completely normal tone of voice:

“What are you doing to me? Why am I here?”

For the first time since his hospital admission, S.E. was lucid, communicative, and oriented to his surroundings. He demonstrated an organized syntax, spontaneous conversational capacity, and an absence of immediate hallucinatory distraction. Crucially, when questioned about the procedure, S.E. possessed complete anterograde amnesia for the electrical shock itself. Unlike patients subjected to Metrazol, who retained vivid, agonizing memories of impending suffocation and panic, S.E. had no awareness of the event whatsoever. He described falling asleep instantaneously without pain, fear, or apprehension.

Encouraged by this monumental clinical success, Cerletti and Bini administered a structured course of eleven electroconvulsive treatments to S.E. over the following month. With each successive generalized seizure, the patient’s psychopathology dissipated. His catatonic posturing vanished; his complex system of persecutory delusions dissolved; and his affective blunting was replaced by warm, appropriate interpersonal engagement. In May 1938, S.E. was officially evaluated by an independent medical board, found to be in complete clinical and social remission, and was formally discharged from the asylum. He returned to Milan, reunited with his wife, and resumed his professional occupation as a clerk—an outcome that was virtually unprecedented for a patient with his clinical history.

6. Initial Efficacy Studies: Clinical Outcomes in Schizophrenia and Psychotic Disorders

Following the stunning remission of S.E., Cerletti and Bini rapidly expanded their investigative scope, initiating large-scale clinical trials on hospitalized cohorts throughout 1938 and 1939. Their initial focus was predominantly centered on the schizophrenic spectrum, providing the psychiatric community with its first systematic empirical datasets regarding electroconvulsive efficacy in psychotic illnesses.

6.1 Stratified Symptom Responses in Catatonia and Paranoid Subtypes

As Cerletti, Bini, and their clinical collaborators treated dozens of schizophrenic patients, they began to recognize that “schizophrenia” was not a monolithic clinical entity with uniform treatment responsiveness. Rather, the efficacy of electroconvulsive therapy exhibited dramatic variance across distinct phenomenological subtypes, as summarized in the stratified outcome data:

Schizophrenic Subtype	Primary Symptom Targets	Average Treatments to Remission	Observed Remission Rate (Early Cohorts)
Catatonic Stupor / Excitement	Mutism, negativism, waxy flexibility, psychomotor exhaustion	4 to 8 sessions	80% – 90%
Acute Paranoid Schizophrenia	Florid delusions, auditory hallucinations, affective panic	8 to 15 sessions	50% – 65%
Hebephrenic / Disorganized	Affective incongruity, profound thought disintegration	12 to 20 sessions	20% – 35%
Chronic “Nuclear” Deterioration	Profound abulia, avolition, institutional inertia (>5 yrs)	15 to 25 sessions	< 15% (Transient)

The most spectacular and rapid clinical victories occurred within the domain of catatonia. Patients presenting in profound catatonic stupor—motionless, refusing oral hydration and nutrition, encopretic, and exhibiting classic waxy flexibility (flexibilitas cerea)—routinely broke their stupor after as few as one to three generalized seizures. Similarly, individuals locked in hyperkinetic catatonic excitement, pacing uncontrollably and facing imminent death from cardiovascular exhaustion and dehydration, experienced profound psychomotor stabilization. For catatonia, electroconvulsive therapy proved to be an acutely life-saving somatic intervention.

In contrast, patients diagnosed with the paranoid subtype of schizophrenia demonstrated moderate, variable responsiveness. In acute cases characterized by rich, florid persecutory ideation and auditory hallucinations of recent onset, ECT induced significant symptom suppression and cognitive restructuring. However, in cases of long-standing, well-encapsulated paranoid systems, the underlying core delusional structure often proved resilient, requiring extensive, prolonged treatment series to achieve partial social remission.

6.2 Longitudinal Remission Rates and Relapse Dynamics

Cerletti and Bini’s observational studies were remarkably modern in their honest documentation of longitudinal trajectory. While initial remission rates were exceedingly high in newly admitted cohorts—often permitting institutional discharge within weeks—the researchers soon encountered the clinical reality of relapse dynamics.

Systematic follow-ups conducted over twelve- to twenty-four-month intervals demonstrated that approximately 30% to 50% of schizophrenic patients who had achieved full clinical remission following an initial course of ten to twelve seizures experienced a return of psychotic symptoms within six to twelve months post-discharge. The Roman clinic observed that relapse was particularly frequent in patients whose home environments were characterized by severe psychological stressors, poverty, or where the onset of the original illness had been insidious rather than acute.

To address this clinical reality, Cerletti and Bini introduced the revolutionary concepts of continuation therapy and maintenance ECT. Rather than terminating all electrical interventions upon hospital discharge, patients demonstrating high relapse risk were scheduled for single, spaced “consolidation” treatments administered every two to four weeks. This proactive maintenance strategy demonstrated a profound capacity to sustain remission, dramatically reducing re-admission rates and marking the conceptual birth of maintenance somatic therapy in biological psychiatry.

6.3 Comparative Symptom Resolution across Diagnostic Subgroups

Through meticulous longitudinal documentation, Cerletti began to draw critical empirical distinctions regarding which specific symptom constellations responded to electrically induced generalized paroxysms. He noted that ECT was essentially an intervention that acted upon active, paroxysmal, and affective neurophysiological turbulence rather than on static, structural cognitive deficits.

Specifically, the Roman studies demonstrated that positive symptoms—hallucinatory perceptions, active delusional pressure, acute psychomotor agitation, and intense affective distress—were highly sensitive to electroconvulsive resolution. Within several treatments, the affective charge attached to persecutory delusions dissipated; patients might still remember the delusional concept intellectually, but it no longer commanded their attention, emotional horror, or behavioral response.

Conversely, negative symptoms—characterized by profound affective flattening, lifelong emotional apathy, poverty of thought, and avolition—showed minimal, if any, lasting improvement. Patients with long-standing “nuclear” or process schizophrenia who had resided in asylum wards for a decade or more frequently experienced a transient clearing of confusion or temporary improvement in personal hygiene during the treatment series, only to regress rapidly to their baseline state of apathy once the seizures ceased. Cerletti’s data-driven analysis thereby prevented ECT from being falsely branded as a universal cure-all, establishing precise, empirically grounded diagnostic boundaries for its clinical deployment.

7. Therapeutic Outcomes in Affective Illness: Unipolar Depression and Bipolar Mania

Although electroconvulsive therapy was initially conceived, designed, and deployed primarily as a treatment for schizophrenia—driven by Meduna’s biological antagonism theory—one of the most significant clinical revelations of Cerletti and Bini’s early research was that the technique exhibited an even more profound, rapid, and definitive efficacy in the realm of affective disorders.

7.1 The Remarkable Efficacy in Severe Melancholia

As the Roman team expanded their patient cohort to include individuals suffering from severe mood disorders, they discovered that unipolar major depression, particularly when presenting with severe melancholic and psychotic features, responded to ECT with unparalleled speed and completeness. Patients in the grips of profound psychotic melancholia—plagued by delusions of guilt, biological unworthiness, somatic putrefaction (Cotard’s syndrome), and intractable psychomotor retardation—demonstrated transformative recoveries.

Whereas schizophrenic patients often required courses ranging from ten to twenty generalized seizures to achieve stable remission, melancholic patients routinely experienced complete clinical resolution within four to eight treatments. The vegetative markers of severe depression began reversing almost immediately:

• Normal sleep architecture, specifically the restoration of slow-wave sleep and resolution of severe terminal insomnia, reappeared after the first two or three seizures.
• Appetite returned, resulting in rapid reversal of severe institutional cachexia.
• Severe, intractable suicidal ideation was extinguished with remarkable reliability, often lifting after a single treatment.

Cerletti and Bini reported remission rates exceeding 85% to 90% in their melancholic cohorts, establishing ECT as the undisputed gold standard for severe, life-threatening depression—a clinical reality that remains entirely unchallenged in modern neurobiology.

7.2 Intervention in Involutional Paranoia and Late-Life Depression

Prior to the introduction of electroconvulsive therapy, one of the most therapeutically devastating diagnoses in psychiatry was involutional melancholia (frequently accompanied by severe involutional paranoia). Typically striking individuals in the fifth or sixth decades of life, this condition was characterized by profound, pacing psychomotor agitation, relentless wringing of hands, unceasing hypochondriacal delusions (e.g., the belief that one’s bowels were permanently turned to stone or that one had contracted an incurable, rotting contagion), and extreme mortality from physical exhaustion, self-starvation, or suicide.

Institutionalized involutional patients typically remained hospitalized until their deaths, maintained in chemical stupor with high doses of paraldehyde, chloral hydrate, or physical restraints. Cerletti and Bini applied their calibrated electroconvulsive method to this demographic with profound results. Late-life patients who had spent years pacing the asylum corridors in relentless agony experienced a complete cessation of their hypochondriacal panic, a clearing of paranoid delusions, and a full restoration of premorbid personality function.

Furthermore, Cerletti observed that electroshock therapy exhibited an exceptionally favorable risk-to-benefit profile in elderly patients compared to the pharmacological alternatives. Heavy sedation with barbiturates or chloral hydrate carried high risks of aspiration pneumonia, cardiovascular collapse, and toxic drug-induced delirium. In contrast, the brief, highly titratable electrical stimulus did not leave toxic chemical residues in aging, compromised hepatic or renal systems. Provided that cardiac screening showed no unstable decompensation, elderly patients tolerated the brief electrical seizures with remarkable physical resilience, transforming the prognosis of late-life psychiatry from chronic decay to rapid institutional discharge.

7.3 Management of Acute Manic Excitement

The clinical efficacy of Cerletti and Bini’s protocol extended with equal potency to the opposite pole of affective illness: acute manic excitement. In the 1930s, acute mania was an exceptionally dangerous medical emergency. Severe manic exhaustion—often termed “delirious mania” or Bell’s mania—frequently proved fatal. Patients locked in continuous, frantic logorrhea, extreme hyperkinesia, sleeplessness, and violent grandiosity would run their cardiovascular systems to the point of circulatory collapse, dehydration, and acute renal failure.

Cerletti and Bini demonstrated that strategic application of electroconvulsive therapy could abruptly abort manic delirium. For patients in acute manic crisis, Bini devised an intensive protocol: rather than administering seizures at the standard interval of two to three times per week, treatments were applied daily, or even twice daily (an early precursor to “block” or multiple-monitored ECT), until the manic frenzy subsided. The effect was immediate. The continuous flight of ideas, extreme motor agitation, and combative impulsivity were rapidly dampened, allowing the patient to rest, accept oral fluids and nourishment, and regain rational contact with their environment. Once the acute manic emergency was terminated, the treatment frequency was tapered, stabilizing the patient’s underlying bipolar mood oscillations without precipitating the chronic physical damage associated with long-term chemical sedation.

8. Comparative Efficacy: Electroconvulsive Therapy versus Pharmacological Shock Therapies

The rapid global adoption of electroconvulsive therapy cannot be understood purely in isolation; it was fundamentally driven by its striking, demonstrable clinical superiority when positioned against the two established pharmacological shock treatments: von Meduna’s Metrazol (Cardiazol) therapy and Sakel’s insulin coma therapy (ICT).

8.1 ECT versus Metrazol (Cardiazol) Convulsive Therapy

From a purely neurophysiological perspective, both Metrazol and electrical stimulation achieved clinical efficacy through the same ultimate mechanism: the elicitation of a generalized bilateral epileptiform seizure. However, from the perspective of human clinical administration, patient safety, and reliability, ECT proved infinitely superior, as delineated in the following clinical comparison:

Clinical Parameter	Metrazol (Cardiazol) Therapy	Cerletti-Bini Electroconvulsive Therapy
Induction Latency	Variable (10 to 60 seconds; occasional failure to seize)	Instantaneous (< 0.1 second)
Subjective Experience	Horrific visceral panic, feeling of suffocation, sense of death	Instant unconsciousness; total retrograde amnesia
Patient Compliance	Severe anticipatory terror; frequent violent resistance	High compliance; absence of procedural terror
Titratability	Crude; dependent on vascular access and erratic metabolism	Precise millisecond duration, voltage, and current regulation
Musculoskeletal Trauma	Extremely high fracture incidence (violent, erratic spasm onset)	Significantly lower fracture rate (smooth, symmetrical onset)
Biochemical Toxicity	Lingering analeptic toxicity; post-ictal nausea, vomiting, headaches	Zero chemical residue; clean, rapid post-ictal clearance

The decisive, overwhelming advantage of ECT over Metrazol lay in the instantaneous abolition of consciousness. When an intravenous injection of Metrazol was pushed, the drug required several circulatory cycles to cross the blood-brain barrier and reach epileptogenic concentration in the cortex. During this harrowing interval, the patient remained fully conscious, experiencing an autonomic storm of terrifying proportions—violent tachycardia, cold sweats, air hunger, and an existential dread described by patients as the literal sensation of dying. Consequently, wards operating on Metrazol were characterized by daily scenes of physical struggle, screaming patients, and severe post-traumatic psychological trauma.

Cerletti and Bini eliminated this human suffering entirely. The passage of an alternating electrical current across the cranium instantly disrupted cortical consciousness within less than 100 milliseconds—vastly faster than the biological processing time of human sensory perception. The patient felt no electrical current, experienced no pain, and possessed no memory of the event whatsoever. Furthermore, because Metrazol triggered erratic, asymmetrical muscular contractions as the chemical diffused unevenly through cerebral tissues, the physical spasms were excessively violent, driving an alarming incidence of bilateral humeral fractures, jaw dislocations, and dorsal vertebral compression fractures. The electrically induced seizure, originating from a symmetrical bilateral trans-cranial field, produced a far more uniform, synchronized motor recruitment, substantially lowering mechanical orthopedic trauma.

8.2 ECT versus Insulin Coma Therapy (ICT)

While Sakel’s insulin coma therapy avoided the violent convulsive panic of Metrazol, its operational profile was deeply problematic. ICT required an extraordinary commitment of institutional infrastructure. A functioning insulin unit demanded a dedicated ward, an exceptionally high nurse-to-patient ratio (often 1:1 or 1:2), and continuous medical supervision throughout the six- to eight-hour duration of the hypoglycemic comas. Clinicians were required to navigate an extraordinarily narrow tightrope between therapeutic coma and lethal hypoglycemic brain death, frequently administering concentrated glucose via nasogastric tubes or emergency intravenous lines to terminate comas before permanent decerebrate posturing ensued.

Despite this extreme vigilance, ICT carried an unavoidable, significant mortality rate. The constant threat of “prolonged” or irreversible coma—where patients failed to awaken following glucose administration due to massive cerebral edema and laminar cortical necrosis—haunted institutional psychiatry. Moreover, while ICT was moderately effective in early-stage paranoid and catatonic schizophrenia, its clinical utility in severe affective melancholia and bipolar mania was conspicuously marginal.

Electroconvulsive therapy, in contrast, was exceptionally cost-effective, rapid, and dramatically safer. An entire clinical ECT session could be executed within twenty to thirty minutes, allowing a single neuropsychiatric team to treat dozens of institutionalized patients in a single morning. Procedure-related mortality in Cerletti and Bini’s early trials was virtually negligible (less than 1 in 10,000 treatments), completely eliminating the constant fear of institutional death associated with insulin wards. Furthermore, ECT’s unmatched therapeutic superiority in depressive and manic states exposed the therapeutic narrowness of ICT, accelerating the transition toward the electrical modality.

8.3 Systematic Side-by-Side Clinical Observational Trials

Between 1938 and 1941, Cerletti and Bini published a series of comprehensive clinical reports comparing patient outcomes across cohorts treated with Metrazol, insulin, and their new electroshock apparatus. Their data demonstrated conclusively that electroconvulsive therapy matched or exceeded the remission rates of Metrazol in schizophrenic cohorts while vastly outpacing both chemical modalities in speed of recovery, patient tolerance, and hospital discharge rates.

Hospital discharge metrics revealed that patients undergoing ECT experienced a marked reduction in their total length of stay compared to those managed with traditional custodial care or prolonged insulin regimens. As these data were translated, published, and presented at international neuropsychiatric congresses, academic clinics across Europe, North America, and South America began shuttering their Metrazol programs and decommissioning their labor-intensive insulin wards. By the onset of the Second World War, Cerletti and Bini’s electrical apparatus had largely supplanted chemical shock therapies, establishing itself as the premier somatic weapon of biological psychiatry.

9. Theoretical Mechanistic Models: Cerletti’s Acroagonine Hypothesis and Neurohumoral Theories

Although the clinical efficacy of electroconvulsive therapy was readily observable and statistically reproducible, the fundamental biological mechanism through which a generalized electrical paroxysm resolved psychiatric symptoms remained an enigma. Cerletti and Bini were not content with mere empirical success; they actively sought to formulate a definitive biological and neurochemical theory of ECT’s therapeutic mechanism.

9.1 The Acroagonine (Vitalizing Substances) Postulate

In his later career, Ugo Cerletti became deeply committed to an intricate humoral and biological theory that he termed the acroagonine hypothesis (derived from the Greek words akros, meaning extreme, and agon, meaning struggle or combat). Cerletti diverged conceptually from Meduna’s strict structural antagonism theory. He argued that the therapeutic agent was not the convulsive motor seizure itself, but rather the brain’s profound, instinctive, biochemical defense reaction to the extreme, life-threatening stress induced by the electrical paroxysm.

Cerletti postulated that when the central nervous system is subjected to the maximal biological shock of an electrical seizure, the cellular elements of the brain—driven into an “extreme struggle” for survival—produce novel, endogenous, highly potent biochemical defense substances: the acroagonines. These substances, Cerletti believed, possessed powerful vitalizing, neurotrophic, and regenerative properties capable of restoring neurovegetative equilibrium, stimulating cellular metabolism, and re-establishing normal psychological operations.

To test this hypothesis empirically, Cerletti conducted a series of daring, unconventional laboratory investigations. He subjected experimental pigs and sheep to prolonged series of electroconvulsive seizures, sacrificed the animals at the peak of their post-ictal defense state, and carefully harvested their brain tissue. Cerletti’s team prepared filtered, concentrated aqueous extracts and suspensions from these electroshocked brains. These extracts—presumed to be rich in freshly synthesized acroagonines—were then administered via intramuscular injections to psychiatric patients suffering from severe depression, melancholia, and chronic schizophrenia, completely independent of any direct electrical shocks.

Cerletti reported that these crude brain extract injections produced demonstrable, albeit modest, clinical improvements in depressive and catatonic symptoms, including increased psychomotor drive, improved appetite, and mood stabilization. While the acroagonine hypothesis was eventually abandoned with the rise of modern biochemical pharmacology and receptor-targeted neurochemistry, it stands as a brilliant, prescient historical intuition. Cerletti had correctly deduced that a generalized seizure triggers the rapid, massive synthesis and release of endogenous neuroprotective, neurotrophic biochemical cascades—a biological reality now firmly validated by contemporary discoveries surrounding Brain-Derived Neurotrophic Factor (BDNF) and seizure-induced adult hippocampal neurogenesis.

9.2 Autonomic and Neurovegetative System Resetting

While Cerletti pursued the humoral acroagonine concept, Lucio Bini turned his intellectual focus toward neurophysiology and neuroanatomy, hypothesizing that the therapeutic mechanism was rooted in an autonomic and neurovegetative system resetting. Bini recognized that the bitemporal path of the electrical current passed directly through deep diencephalic structures, most notably the hypothalamus, the thalamus, and the periaqueductal gray.

Bini argued that psychiatric illnesses—particularly affective melancholia and catatonia—represented fundamental disturbances in the central vegetative centers of the brain that govern autonomic equilibrium, sleep-wake cycles, neuroendocrine regulation, visceral tone, and affective drives. He observed that the immediate aftermath of an electrically induced seizure was marked by a profound autonomic surge: transient hypertension, pupillary dilation, massive salivary and bronchial secretion, followed immediately by profound parasympathetic rebound, bradycardia, and peripheral vasodilation.

Bini hypothesized that the intense, synchronized paroxysmal discharge obliterated pathological, reverberating neuronal feedback loops within the diencephalon. By violently depolarizing and exhausting these hyperactive or dysregulated circuits, the electroconvulsive paroxysm operated as a physiological “reset switch” for the vegetative nervous system. This hypothesis neatly accounted for the rapid, near-universal restoration of biological vegetative functions—spontaneous sleep patterns, appetite, gastrointestinal motility, and libido—consistently observed in patients recovering from melancholia under ECT.

9.3 Neurophysiological and Electroencephalographic Correlates

The advent of electroencephalography (EEG), pioneered by Hans Berger in the late 1920s and early 1930s, provided Cerletti and Bini with a sophisticated new tool to investigate the direct electrophysiological transformations wrought by electroconvulsive therapy. Early EEG recordings of patients undergoing ECT revealed profound, predictable alterations in cerebral electrical architecture.

During the actual seizure, the EEG captured the classic, high-amplitude, synchronized poly-spike and slow-wave discharges characteristic of a grand mal epileptic fit. However, the most clinically revealing neurophysiological data emerged during the post-ictal and inter-ictal phases. Immediately following the cessation of clonic motor activity, the EEG demonstrated a period of profound electrical silence or diffuse, high-amplitude, ultra-slow delta rhythm activity (typically 1 to 3 Hz) across the entire cerebral cortex. In patients receiving repetitive treatments over several weeks, this slow-wave delta pattern persisted as a continuous baseline feature on the EEG.

Cerletti and Bini observed a direct positive correlation between the emergence and stability of this generalized post-ictal delta slowing and the degree of clinical symptom remission. Patients who exhibited rapid, robust delta wave stabilization routinely experienced the most complete clearing of psychotic agitation and depressive affect. They conceptualized this generalized slowing not as brain damage, but as a state of deep, restorative cerebral inhibition—a profound neurophysiological stabilization that dampened cortical hypersensitivity and severed the rigid, fragmented circuits perpetuating psychiatric illness. Furthermore, these electrophysiological findings dealt a fatal blow to Meduna’s original biological antagonism theory: it became increasingly clear that the therapeutic efficacy of the seizure was not due to an anatomical combat between glia and neurons, but rather to massive, dynamic shifts in global neurophysiological synchronization and cortical inhibition.

10. Methodological Limitations and Adverse Effect Profiles in Early Cerletti-Bini Trials

Despite the historic clinical efficacy and revolutionary therapeutic breakthroughs achieved by Cerletti and Bini, their early protocols were bound by the pharmacological and technical limitations of the 1930s. The early era of electroconvulsive therapy was characterized by notable adverse effect profiles and substantial methodological deficits that would take decades of subsequent biomedical innovation to refine and resolve.

10.1 Musculoskeletal Complications and the ‘Unmodified’ State

The single greatest clinical hazard of early electroconvulsive therapy stemmed from the fact that it was delivered in an entirely unmodified state. In the 1930s and 1940s, the concepts of modern clinical anesthesia, short-acting intravenous barbiturates, and neuromuscular paralytic agents did not exist within the routine psychiatric setting. Consequently, the patient was fully awake prior to the shock, and the induced generalized cerebral seizure produced an unfettered, violent motor convulsion involving the maximal contractile force of every major muscle group in the human body.

The physiological force generated by these uninhibited, simultaneous muscular contractions was massive. The sudden, violent transition into the tonic phase—where the paraspinal muscles, quadriceps, and abdominal musculature contracted with maximal tetanic force—placed tremendous mechanical compression vectors across the axial skeleton. As a consequence, thoracic vertebral compression fractures emerged as a frequent and serious complication of early unmodified ECT. Clinical audits from the early 1940s indicated that mid-thoracic vertebral wedging (typically between T4 and T8) occurred in a significant percentage of patients, with some institutional estimates ranging between 10% and 30%, depending on the age and bone density of the cohort.

Additionally, clinicians frequently encountered mechanical dislocations of the temporomandibular joints, humeral dislocations, and, less frequently, femoral neck fractures. To mitigate these devastating musculoskeletal complications, Cerletti and Bini had to devise intensive physical restraining and positioning techniques. Patients were placed on hard, flat wooden tables covered only by a thin mat; padded firm pillows were wedged beneath the thoracic spine to maintain hyper-extension and distribute axial compression forces; padded mouth gags were inserted to prevent tongue lacerations and dental fractures; and multiple trained male orderlies were positioned around the bed to manually hold the patient’s limbs in controlled adduction during the convulsive paroxysm. While these physical protocols reduced peripheral limb fractures, they remained an imperfect, stressful, and physically traumatic solution to an inherent biophysical problem.

10.2 Cognitive Sequelae, Retrograde Amnesia, and Post-Ictal Confusion

The primary neurological adverse effects documented in Cerletti and Bini’s early patient cohorts were cognitive in nature: specifically, post-ictal delirium and memory impairment. Because Bini’s prototype machine delivered an unmodified, continuous alternating sinusoidal current (sine-wave), and because the electrodes were arranged in a bilateral bitemporal configuration, vast quantities of electrical energy coursed directly through both temporal lobes, heavily affecting the medial temporal structures, the hippocampus, and the entorhinal cortices bilaterally.

Following recovery from the immediate post-ictal coma, patients routinely entered a state of transient acute confusion lasting from thirty minutes to several hours. During this interval, they exhibited disorientation to time, place, and person, perseverative questioning, and mild psychomotor agitation. With cumulative treatments delivered over a multi-week course, this cognitive disturbance coalesced into pronounced anterograde and retrograde amnesia:

• Anterograde Amnesia: An acute, transient inability to retain and consolidate novel informational traces, making it difficult for the patient to remember daily events, recent conversations, or new hospital routines.
• Retrograde Amnesia: A temporally graded loss of previously acquired memories. Patients frequently demonstrated patchy, dense memory gaps extending back several weeks, months, or occasionally years preceding the treatment course, displaying Ribot’s law of retrograde amnesia (older, well-consolidated memories were preferentially spared over newly formed memories).

Cerletti and Bini meticulously documented these cognitive phenomena. They observed that in the vast majority of patients, the profound anterograde amnesia resolved spontaneously within several weeks to two months following the cessation of the electroconvulsive series. Retrograde memory gaps similarly shrank over time, though patients occasionally retained permanent, circumscribed amnesic lacunae for the temporal window immediately surrounding their hospital admission and treatment course. While early critics seized upon these memory deficits as evidence of irreversible intellectual destruction, Cerletti maintained that the cognitive disruption was largely reversible and represented a minor clinical price to pay for the permanent alleviation of intractable, life-threatening psychosis and suicide.

10.3 Methodological Deficits in Early Clinical Study Designs

When evaluated through the lens of modern evidence-based medicine and twenty-first-century clinical epidemiology, the original efficacy studies conducted by Cerletti, Bini, and their early European contemporaries possessed substantial methodological limitations. These deficits were not unique to the Roman school; they reflected the universal state of medical and psychiatric research methodology in the pre-World War II era.

First and foremost, early ECT trials completely lacked standardized diagnostic criteria. The diagnostic systems of the late 1930s relied heavily upon idiosyncratic, institutional interpretations of Kraepelinian and Bleulerian frameworks. Diagnostic categories such as “dementia praecox,” “paraphrenia,” and “involutional psychosis” were fluid, heterogeneous, and applied without the operationalized boundaries of modern instruments like the DSM or ICD. What one clinician designated as catatonic schizophrenia, another might classify as depressive stupor, introducing profound heterogeneity into treatment cohorts.

Second, the early studies possessed no standardized, validated psychiatric rating scales. Outcome assessments did not utilize validated quantitative metrics such as the Hamilton Depression Rating Scale (HAM-D) or the Positive and Negative Syndrome Scale (PANSS), which were only developed decades later. Instead, clinical efficacy was measured through subjective clinical observations, narrative case histories, and crude binary administrative endpoints, such as “cured,” “socially recovered,” “improved,” or “unimproved.”

Finally, the early research lacked prospective randomized controlled trials (RCTs) and sham-controlled experimental designs. Patients were not randomized to treatment versus control groups, nor were sham-ECT conditions (administering anesthesia without electrical current) incorporated to isolate the biological impact of the seizure from the powerful non-specific psychological effects of dramatic institutional intervention, intensive nursing care, and physician attention. Furthermore, outcome evaluations were conducted directly by the unblinded treating psychiatrists—Cerletti, Bini, and their devoted assistants—who possessed a significant intellectual, academic, and emotional investment in the success of the novel modality. While subsequent modern sham-controlled trials have robustly confirmed the profound biological efficacy of ECT, the methodological limitations of the 1930s trials left early ECT literature vulnerable to legitimate scientific critique regarding investigator bias and experimental rigor.

11. Global Dissemination, Systematic Replications, and Standardization of Findings

The transformative clinical potential of Cerletti and Bini’s discovery, combined with its profound operational advantages over chemical convulsive therapies, led to an explosive, unprecedented global dissemination. Within a few short years, the Roman protocol was replicated, industrialized, and standardized across psychiatric institutions throughout the Western world.

11.1 Lothar Kalinowsky and the International Diffusion of ECT

The primary catalyst for the rapid international diffusion of electroconvulsive therapy was the German-American neuropsychiatrist Lothar B. Kalinowsky. Having trained in Berlin, Kalinowsky fled Nazi Germany due to his Jewish heritage and settled in Rome, where he joined Cerletti’s department at the University of Rome in the mid-1930s. Kalinowsky was an active participant and eyewitness to Cerletti and Bini’s earliest animal experiments and was present in the clinical amphitheater during the historic April 1938 human trials on S.E.

Recognizing the profound significance of what he had witnessed, Kalinowsky became the principal international ambassador of the Roman school. In 1939, as the geopolitical crisis in Europe escalated, Kalinowsky relocated to Paris and then to London, demonstrating the electroconvulsive technique to skeptical British clinicians at the Maudsley Hospital. In 1940, Kalinowsky emigrated to the United States, securing appointments at the New York State Psychiatric Institute and Columbia University.

Kalinowsky brought with him the exact blueprints, circuit schematics, and clinical protocols formulated by Lucio Bini. He constructed the first operational electroshock machines in the United States, demonstrating the technique to prominent American alienists. The response across the American psychiatric establishment was immediate. Major academic medical centers—including Harvard, Johns Hopkins, and the Mayo Clinic—launched immediate replication studies. These independent multicenter trials universally validated Cerletti and Bini’s findings, confirming that the electrical modality was vastly safer, cheaper, and more effective than Metrazol or insulin coma therapy, cementing ECT’s role as the premier somatic intervention across the American continent.

11.2 Technological Evolution of the Bini Apparatus Worldwide

As the international psychiatric community adopted electroconvulsive therapy, the engineering of the delivery apparatus underwent rapid, sophisticated technological evolution. Biomedical manufacturers across Europe and the United States began producing commercial, industrialized versions of Bini’s original prototype, standardizing electrical delivery and integrating novel safety circuits.

One of the most consequential technical innovations occurred in the domain of stimulus wave-forms. Bini’s original machine delivered continuous, alternating sine-wave currents derived directly from commercial electrical lines. Biophysically, a sinusoidal wave-form is extraordinarily inefficient at triggering neuronal depolarization. Because a sine wave rises and falls gradually, vast quantities of electrical current are delivered during the sub-threshold phases of the cycle—energy that fails to depolarize the neuron yet passes through brain tissue, generating unnecessary electrical charge, heat, and structural disturbance.

In the 1940s and early 1950s, biomedical researchers—most notably Paul Friedman and later Wladimir Liberson—introduced the concept of brief-pulse stimulation. Rather than delivering continuous sine-wave current, novel machines were engineered to deliver ultra-short, square-wave electrical pulses (typically 0.5 to 2.0 milliseconds in duration). These brief pulses matched the physiological chronaxie of neuronal membranes with absolute efficiency, triggering complete generalized seizures while delivering only a fraction (frequently less than one-third) of the total electrical energy mandated by early sine-wave machines. The widespread adoption of brief-pulse square-wave stimuli drastically reduced the severity of post-ictal confusion and accelerated cognitive recovery.

Concurrently, in 1958, British psychiatrist Lancaster and colleagues introduced unilateral electrode placement (typically over the non-dominant, right cerebral hemisphere) as an alternative to Cerletti and Bini’s original bitemporal placement. By concentrating the electrical vector exclusively over the non-dominant hemisphere, unilateral ECT completely spared the dominant left hemisphere (responsible for verbal memory and linguistic processing), virtually eliminating verbal retrograde amnesia while preserving robust clinical antidepressant efficacy.

11.3 Integration of Pharmacological Modifications

The most profound transformation in the history of electroconvulsive therapy—and the development that firmly elevated it into a modern, humane surgical-level procedure—was the introduction of pharmacological modifications. Throughout the first decade of its use, the threat of vertebral compression fractures and severe musculoskeletal trauma remained ECT’s Achilles’ heel.

The first decisive breakthrough occurred in 1940, when American neuropsychiatrist A.E. Bennett introduced the botanical neuromuscular blocking agent curare (specifically an extract termed Intocostrin) into clinical ECT practice. By administering curare intravenously prior to the delivery of the electrical stimulus, Bennett successfully paralyzed the patient’s skeletal muscles. When the electrical charge was delivered, the brain underwent a full, classic neurophysiological generalized grand mal seizure, but the peripheral motor manifestation was reduced to a soft, harmless muscular twitch. The incidence of vertebral compression fractures dropped to zero overnight.

However, curare was difficult to dose, possessed lingering histaminergic side effects, and carried a high risk of prolonged respiratory paralysis. The true medical standard of care emerged in the early 1950s with two monumental pharmacological innovations:

1. The Introduction of Succinylcholine: In 1951, the synthetic, ultra-short-acting depolarizing neuromuscular blocker succinylcholine (suxamethonium) was introduced. Succinylcholine produced complete, profound skeletal muscle relaxation within forty-five seconds of intravenous push and was metabolized rapidly by plasma pseudocholinesterase within three to five minutes, restoring spontaneous respiration without lingering muscular weakness.
2. The Integration of Short-Acting Barbiturate Anesthesia: Concurrently, clinicians integrated ultra-short-acting intravenous anesthetics (most prominently methohexital and thiopental). Patients were no longer conscious when paralyzed; they were gently and painlessly put to sleep with an intravenous anesthetic, ventilated with 100% positive-pressure oxygen, administered succinylcholine for absolute muscular paralysis, and then delivered the calibrated brief-pulse electrical stimulus.

This triumphant synthesis established modified ECT as the universal medical gold standard. Pharmacological modification fully validated Cerletti and Bini’s foundational scientific premise: the clinical therapeutic efficacy of electroconvulsive therapy was mediated entirely by the cerebral neurophysiological paroxysm, and in no way required the peripheral, violent mechanical motor convulsion. With the eradication of physical fractures, panic, and pain, ECT was transformed into one of the safest medical procedures in all of clinical medicine.

12. Enduring Scientific Legacy: The Trajectory of Modern ECT Derived from Cerletti and Bini’s Research

More than eight decades after Ugo Cerletti and Lucio Bini conducted their first daring experiments on the floor of the Roman slaughterhouse and in the clinical theater of the University of Rome, electroconvulsive therapy remains one of the most durable, resilient, and scientifically fascinating modalities in modern medicine. Far from being discarded as a primitive relic of historical psychiatry, ECT has undergone an extraordinary scientific renaissance.

12.1 Refinement of Clinical Indications in Modern Neuropsychiatry

In contemporary clinical practice, electroconvulsive therapy is governed by rigorous, evidence-based international guidelines formulated by bodies such as the American Psychiatric Association (APA), the National Institute for Health and Care Excellence (NICE), and the World Federation of Societies of Biological Psychiatry (WFSBP). The clinical indications have evolved to reflect the exact empirical realities first observed by Cerletti and Bini:

First and foremost, modern ECT is recognized as the single most effective intervention in existence for treatment-resistant major depressive disorder (TRD), particularly when accompanied by psychotic features or severe melancholia. In clinical populations where multiple modern pharmacological agents—including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclics, and atypical antipsychotic augmentations—have entirely failed, ECT routinely achieves remission rates between 70% and 80%. Furthermore, in clinical scenarios involving acute, lethal suicidality, severe depressive stupor, or profound cachexia, ECT remains the frontline, acutely life-saving intervention of choice due to its rapid onset of action.

Second, modern neuropsychiatry has reaffirmed Cerletti’s original observations regarding the supremacy of ECT in the management of catatonia. Whether arising secondary to a mood disorder, schizophrenia, or an underlying general medical condition, catatonia demonstrates an unprecedented 80% to 90% response rate to ECT, routinely breaking intractable states of catatonic stupor or malignant catatonic excitement where high-dose benzodiazepines fail. It also serves as an absolute frontline treatment for Neuroleptic Malignant Syndrome (NMS), a life-threatening complication of antipsychotic pharmacotherapy.

Finally, ECT occupies an essential clinical role in bipolar disorder, providing rapid stabilization for severe, medication-refractory acute mania, delirious mania, and treatment-resistant bipolar depression, confirming the broad, multi-dimensional efficacy profiles documented in the Roman clinic’s earliest publications.

12.2 Neurobiological Validation of Early Empirical Observations

Perhaps the most remarkable aspect of Cerletti and Bini’s legacy is the degree to which twenty-first-century molecular neuroscience and neuroimaging have validated their early, speculative mechanistic hypotheses. Where Cerletti once hypothesized hypothetical “acroagonines”—protective, vitalizing substances synthesized by the brain during the existential stress of a seizure—modern molecular biology has identified specific, quantifiable neurotrophic cascades.

Contemporary molecular studies have conclusively demonstrated that electroconvulsive seizures trigger a massive, immediate up-regulation of Brain-Derived Neurotrophic Factor (BDNF) and its high-affinity receptor, Tropomyosin receptor kinase B (TrkB), within the hippocampus and prefrontal cortex. This seizure-induced BDNF surge drives dramatic cellular repair, promoting dendritic branching, synaptogenesis, and profound adult neurogenesis within the subgranular zone of the dentate gyrus. Structural magnetic resonance imaging (MRI) studies have longitudinally confirmed that patients completing a clinical course of ECT demonstrate significant, measurable volume increases in the hippocampus, amygdala, and anterior cingulate cortex—volumetric neuroplastic expansion that directly correlates with clinical symptom remission.

Furthermore, functional neuroimaging (fMRI) has transformed Bini’s concept of “neurovegetative resetting” into the language of modern network neuroscience. Functional connectivity analyses reveal that severe depression is characterized by profound hyper-connectivity and hyper-synchrony within the Default Mode Network (DMN)—a functional brain network mediating morbid internal rumination, self-referential negative affect, and depressive fixation. Modern fMRI investigations show that a course of electroconvulsive therapy directly suppresses this pathological hyper-connectivity, breaking the rigid, reverberating circuits of the DMN and restoring healthy, flexible functional connectivity between the frontal, limbic, and diencephalic networks. Cerletti and Bini’s intuitive clinical deductions have thus been thoroughly vindicated by modern molecular genetics and functional neurobiology.

12.3 Historical Appraisal of Cerletti and Bini’s Epistemic Contribution

When evaluated in the broader context of the history of medicine, the contribution of Ugo Cerletti and Lucio Bini stands as an extraordinary triumph of experimental science over clinical despair. Operating in an era completely devoid of modern psychotropic drugs, computational modeling, or high-resolution neuroimaging, they approached one of the most agonizing, poorly understood frontiers of human disease with intellectual courage, technical ingenuity, and ethical responsibility.

Rather than recklessly rushing into human experimentation, Cerletti and Bini constructed a preclinical safety framework that was decades ahead of its time. Their systematic sequence of investigations—delineating lethal trans-thoracic electrocution from trans-cranial stimulation in canines, quantitatively verifying mammalian safety thresholds in the slaughterhouses of Rome, and histopathologically proving the structural integrity of post-ictal brain tissue—demonstrates a commitment to medical ethics and the scientific method that deserves enduring admiration.

By transforming electricity from a deadly industrial hazard into a calibrated, life-saving neuropsychiatric instrument, Cerletti and Bini liberated psychiatric practice from the terrors of chemical convulsive agents and the custodial paralysis of the asylum era. Their work directly catalyzed the birth of modern biological psychiatry, forever altering our conceptualization of the relationship between electrical neurophysiology, cerebral circuitry, and human mental health. The modern patient who awakens peacefully from a brief, modified ECT treatment—free from suicidal agony, reconnected with reality, and restored to their family—owes their life and cognitive health directly to the intellectual foundation laid in Rome in April 1938 by Ugo Cerletti and Lucio Bini.

Conclusion

The odyssey of electroconvulsive therapy—from its conceptual genesis in 1930s Rome to its contemporary position as an indispensable pillar of modern neurobiology—represents one of the most compelling narratives in the history of clinical medicine. Faced with the devastating human toll of severe schizophrenia, catatonic stupor, and intractable melancholia, Ugo Cerletti and Lucio Bini recognized that empirical medical progress demanded both bold physiological intervention and uncompromising scientific rigor. Their collaboration bridged the gap between microscopic neuropathology and quantitative biophysical engineering, yielding an apparatus and a method that rendered generalized seizure induction safe, instantaneous, reproducible, and humane.

Through their meticulous initial trials, Cerletti and Bini established the fundamental clinical parameters that continue to govern electroconvulsive therapy to this day. They demonstrated the all-or-none dynamics of the seizure threshold, documented the crucial distinction between ineffective sub-convulsive stimulations and fully propagated therapeutic paroxysms, identified the profound, rapid responsiveness of affective melancholia and catatonia over chronic process schizophrenia, and anticipated modern maintenance strategies to combat longitudinal relapse. Furthermore, Cerletti’s humoral intuition regarding endogenous “acroagonines” laid the intellectual conceptual framework for modern discoveries in neurogenesis, neuroplasticity, and neurotrophic factor signaling.

As electroconvulsive therapy continues to evolve through the integration of individualized brief-pulse stimulation, advanced algorithmic seizure titration, unilateral non-dominant electrode placements, and sophisticated ultra-short-acting pharmacological modifications, its core biological reality remains unchanged: the therapeutic paroxysm first harnessed by Cerletti and Bini represents one of the most acutely effective, biologically transformative interventions available to modern clinical neuroscience. In an era where neuropsychiatry increasingly seeks to understand the brain through complex network dynamics and neuroplastic restructuring, the pioneering breakthrough achieved by Ugo Cerletti and Lucio Bini in April 1938 stands not merely as a historical curiosity, but as an enduring, foundational triumph of medical science.

References

Accornero, F. (1988). An eyewitness account of the historic first electroshock treatment. Convulsive Therapy, 4(1), 34–39. https://pubmed.ncbi.nlm.nih.gov/11940989/

American Psychiatric Association. (2001). The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging (2nd ed.). American Psychiatric Publishing. https://www.psychiatryonline.org

Bennett, A. E. (1940). Preventing traumatic complications in convulsive shock therapy by curare. Journal of the American Medical Association, 114(4), 322–324. https://doi.org/10.1001/jama.1940.02810040034008

Bini, L. (1938). Experimental researches on epileptic attacks induced by the electric current. American Journal of Psychiatry, 94(Suppl 6), 172–174. https://doi.org/10.1176/ajp.94.6S.172

Cerletti, U. (1940). L’Elettroshock. Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali, 64, 209–310.

Cerletti, U. (1950). Old and new information about electroshock. American Journal of Psychiatry, 107(2), 87–94. https://doi.org/10.1176/ajp.107.2.87

Cerletti, U. (1956). Electroshock therapy. In A. M. Sackler et al. (Eds.), The Great Physiodynamic Therapies in Psychiatry: An Historical Reappraisal (pp. 91–120). Hoeber-Harper.

Cerletti, U., & Bini, L. (1938). L’Elettroshock. Bollettino della Reale Accademia Medica di Roma, 64, 136–138.

Endler, N. S. (1988). The origins of electroconvulsive therapy (ECT). Convulsive Therapy, 4(1), 5–23. https://pubmed.ncbi.nlm.nih.gov/11940987/

Fink, M. (1979). Convulsive Therapy: Theory and Practice. Raven Press.

Fink, M. (2009). Electroconvulsive Therapy: A Guide for Professionals & Their Patients. Oxford University Press. https://doi.org/10.1093/med/9780195365733.001.0001

Kalinowsky, L. B. (1986). Fifty years of biological treatments: Personal impressions and reflections. Comprehensive Psychiatry, 27(5), 403–409. https://doi.org/10.1016/0010-440X(86)90040-5

Kalinowsky, L. B., & Hoch, P. H. (1946). Shock Treatments and Other Somatic Procedures in Psychiatry. Grune & Stratton.

Lancaster, N. P., Steinert, R. R., & Frost, I. (1958). Unilateral electro-convulsive therapy. The Journal of Mental Science, 104(434), 221–227. https://doi.org/10.1192/bjp.104.434.221

Meduna, L. (1935). Versuche über die biologische Beeinflussung des Ablaufes der Schizophrenie: Campher- und Cardiazolkrämpfe. Zeitschrift für die gesamte Neurologie und Psychiatrie, 152(1), 235–262. https://doi.org/10.1007/BF02865703

Passione, R. (2004). Italian psychiatry in an international context: Ugo Cerletti and the case of electroshock. History of Psychiatry, 15(1), 83–104. https://doi.org/10.1177/0957154X04039352

Shorter, E., & Healy, D. (2007). Shock Therapy: A History of Electroconvulsive Treatment in Mental Illness. Rutgers University Press. https://www.rutgersuniversitypress.org